Fusion Antibodies PLC (FAB) — Capital Reinvestment Ratio
Latest as of March 2022:
0.39x
Fusion Antibodies PLC (FAB) has a Capital Reinvestment Ratio of 0.39x as of March 2022, meaning it reinvests 0% of its operating cash flow (GBX174.00K) in capital expenditures (GBX67.00K). See cash generation quality of Fusion Antibodies PLC to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.39x
Capex / Operating Cash Flow
Operating Cash Flow
GBX174.00K
GBX
Capital Expenditures
GBX67.00K
GBX
Data as of
Mar 2022
Most recent filing
Fusion Antibodies PLC Capital Reinvestment Ratio (2016–2018)
This chart tracks Fusion Antibodies PLC's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Fusion Antibodies PLC (2016–2018)
Year-by-year Capital Reinvestment Ratio for Fusion Antibodies PLC from 2016 to 2018. For live market cap and broader valuation context, see Fusion Antibodies PLC (FAB) total market value.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 5.76x | GBX77.19K | GBX444.60K | ▲ +5481.8% |
| 2016 | 0.10x | GBX346.57K | GBX35.76K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow